
    
      A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the
      PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with
      non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient
      breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma
      (HCC).
    
  